NSE WOCKPHARMA · BSE 532300 · Biotechnology & Drugs · NIFTY 500
Wockhardt Share Price
Wockhardt Overview
Where the price stands, how it has moved and how it sits against its averages.
Wockhardt shares last traded at ₹2,194.20 on the NSE, up 0.30% on the day. That is 9.3% below the 52-week high of ₹2,420.00 and 101.9% above the 52-week low of ₹1,086.80. The stock trades at 87.12× earnings, above the sector average of 33.72. Its market value is ₹35,631 Cr.
Price returns
Share price growth a year (CAGR): 3 years ▲ +110.5% · 5 years ▲ +41.1% · 10 years ▲ +10.4%
Against the market: 1 Month ▲ +22.81% · 3 Months ▲ +18.30% · 6 Months ▲ +83.96% · This year ▲ +77.14% · 1 Year ▲ +80.90%
Shading grows with the size of the move. We ask our data provider for a newer price every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next check from Mon 26 Oct, 9:15 AM. Its quotes are not real-time — the time at the top shows how current the price is.
Moving averages — price is above 5 of 6
- 5-day average₹2,251.14 ▼ price 2.5% below
- Today's price₹2,194.20
- 10-day average₹2,167.91 ▲ price 1.2% above
- 20-day average₹2,099.48 ▲ price 4.5% above
- 50-day average₹1,985.06 ▲ price 10.5% above
- 100-day average₹1,907.71 ▲ price 15.0% above
- 300-day average₹1,634.13 ▲ price 34.3% above
Each average is the mean closing price over that many trading days; averages above the current price sit higher on the ladder.
Wockhardt Financial Results
Revenue and net profit in ₹ crore, with the full statements underneath.
Year by year
| Fiscal year | Revenue | Growth | Net profit | Net margin | EPS | Dividend |
|---|---|---|---|---|---|---|
| FY 2026 | ₹3,373 Cr | ▲ +12.0% | ₹213 Cr | 6.3% | ₹13.10 | — |
| FY 2025 | ₹3,012 Cr | ▲ +7.6% | −₹47 Cr | −1.6% | −₹3.00 | — |
| FY 2024 | ₹2,798 Cr | ▲ +5.5% | −₹463 Cr | −16.5% | −₹32.10 | — |
| FY 2023 | ₹2,651 Cr | ▼ −17.9% | −₹559 Cr | −21.1% | −₹38.79 | — |
| FY 2022 | ₹3,230 Cr | ▲ +19.3% | −₹244 Cr | −7.6% | −₹20.24 | — |
| FY 2021 | ₹2,708 Cr | ▼ −4.8% | ₹686 Cr | 25.3% | −₹24.91 | — |
| FY 2020 | ₹2,844 Cr | — | −₹69 Cr | −2.4% | −₹13.64 | — |
Quarter by quarter
| Quarter | Revenue | vs prev. qtr | Net profit | Net margin | EPS |
|---|---|---|---|---|---|
| Q1 FY27 | ₹929 Cr | ▼ −3.7% | ₹106 Cr | 11.4% | ₹6.55 |
| Q4 FY26 | ₹965 Cr | ▲ +8.7% | ₹166 Cr | 17.2% | ₹10.20 |
| Q3 FY26 | ₹888 Cr | ▲ +13.6% | ₹59 Cr | 6.6% | ₹3.61 |
| Q2 FY26 | ₹782 Cr | ▲ +6.0% | ₹78 Cr | 10.0% | ₹4.81 |
| Q1 FY26 | ₹738 Cr | ▼ −0.7% | −₹90 Cr | −12.2% | −₹5.53 |
| Q4 FY25 | ₹743 Cr | ▲ +3.1% | −₹25 Cr | −3.4% | −₹1.57 |
| Q3 FY25 | ₹721 Cr | ▼ −10.9% | ₹14 Cr | 1.9% | ₹0.91 |
| Q2 FY25 | ₹809 Cr | — | −₹22 Cr | −2.7% | −₹1.47 |
Balance sheet — FY26
- Total assets₹8,615 Cr
- Total liabilities₹3,675 Cr
- Shareholders' equity₹4,940 Cr
- Total debt₹2,233 Cr
- Cash & investments₹629 Cr
- Current ratio1.66×
- Revenue growth, 5 yr4.49% a year
- Operating margin (TTM)14.11%
- Net margin (TTM)11.62%
Cash flow — FY26
Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.
Full financial statements, FY20–FY26
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Total revenue | 2,843.99 | 2,708.30 | 3,230.00 | 2,651.00 | 2,798.00 | 3,012.00 | 3,373.00 |
| Cost of revenue | 1,328.12 | 1,268.66 | 1,354.00 | 1,176.00 | 1,240.00 | 1,225.00 | 1,243.00 |
| Gross profit | 1,515.87 | 1,439.64 | 1,876.00 | 1,475.00 | 1,558.00 | 1,787.00 | 2,130.00 |
| Operating expenses | 2,970.37 | 3,157.37 | 3,362.00 | 2,972.00 | 2,944.00 | 2,832.00 | 3,055.00 |
| Operating income | −126.38 | −449.07 | −132.00 | −321.00 | −146.00 | 180.00 | 318.00 |
| Depreciation | 224.14 | 246.02 | 247.00 | 251.00 | 223.00 | 217.00 | 227.00 |
| Profit before tax | −342.04 | −568.34 | −411.00 | −624.00 | −420.00 | −16.00 | 238.00 |
| Tax | −204.09 | −271.61 | −132.00 | −3.00 | 52.00 | 41.00 | 39.00 |
| Net profit | −69.22 | 686.06 | −244.00 | −559.00 | −463.00 | −47.00 | 213.00 |
| EPS (₹) | −13.64 | −24.91 | −20.24 | −38.79 | −32.10 | −3.00 | 13.10 |
| Dividend per share (₹) | — | — | — | — | — | — | — |
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Total assets | 8,178.91 | 7,772.69 | 8,243.00 | 7,683.00 | 7,649.00 | 8,135.00 | 8,615.00 |
| Current assets | 2,429.83 | 2,424.38 | 2,589.00 | 2,208.00 | 2,184.00 | 2,569.00 | 2,697.00 |
| Cash & short-term investments | 219.35 | 232.57 | 381.00 | 90.00 | 505.00 | 534.00 | 629.00 |
| Inventory | 711.87 | 831.15 | 842.00 | 726.00 | 687.00 | 823.00 | 937.00 |
| Property, plant & equipment | 3,315.35 | 2,914.27 | 2,860.00 | 2,436.00 | 2,309.00 | 2,231.00 | 2,289.00 |
| Total liabilities | 5,507.24 | 4,395.93 | 4,394.00 | 4,329.00 | 4,290.00 | 3,782.00 | 3,675.00 |
| Current liabilities | 3,497.18 | 3,118.22 | 3,207.00 | 3,435.00 | 2,791.00 | 2,042.00 | 1,622.00 |
| Total debt | 3,582.26 | 2,672.95 | 2,198.00 | 2,184.00 | 2,356.00 | 2,021.00 | 2,233.00 |
| Total equity | 2,671.67 | 3,376.76 | 3,849.00 | 3,354.00 | 3,359.00 | 4,353.00 | 4,940.00 |
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| From operations | 648.96 | −287.32 | 413.00 | 153.00 | 219.00 | −22.00 | 386.00 |
| From investing | −155.53 | 1,470.10 | −201.00 | −125.00 | −137.00 | −783.00 | −241.00 |
| From financing | −679.58 | −1,170.82 | −71.00 | −315.00 | 334.00 | 409.00 | −54.00 |
| Capital expenditure | −172.38 | −165.73 | −212.00 | −209.00 | −216.00 | −365.00 | −364.00 |
| Dividends paid | — | — | — | — | — | — | — |
| Net change in cash | −178.00 | 12.91 | 138.00 | −280.00 | 415.00 | −393.00 | 105.00 |
Wockhardt vs Peers
Side by side with other biotechnology & drugs companies. The small bars compare each column.
| Company | Price | Change | Market cap | P/E | P/B | ROE (5 yr) | Net margin | Div. yield |
|---|---|---|---|---|---|---|---|---|
| Wockhardt This stock | ₹2,194.20 | ▲ +0.30% | ₹35,631 Cr | 87.12 | 7.22 | −5.77% | 11.62% | 0.00% |
| Sun Pharmaceutical Industries | ₹1,860.00 | ▲ +1.09% | ₹4,46,266 Cr | 38.40 | 5.55 | 14.22% | 19.12% | 0.83% |
| Divi's Laboratories | ₹9,475.00 | ▼ −0.59% | ₹2,51,531 Cr | 73.32 | 11.48 | 16.87% | 24.32% | 0.41% |
| Torrent Pharmaceuticals | ₹4,915.15 | ▲ +0.94% | ₹1,86,950 Cr | 72.73 | 19.22 | 23.00% | 15.29% | 0.80% |
| Cipla | ₹1,383.00 | ▼ −0.42% | ₹1,11,727 Cr | 27.57 | 3.33 | 14.47% | 13.74% | 0.92% |
| Zydus Lifesciences | ₹1,195.20 | ▼ −1.39% | ₹1,19,222 Cr | 21.19 | 4.24 | 17.90% | 18.51% | 0.09% |
Peer prices and ratios as last reported by the data provider. Company names link to their own pages.
Wockhardt Key Metrics
Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.
Valuation The price against earnings, book value and sales
Profitability Of every ₹100 of sales, how much is kept?
Returns & efficiency How well does it use its money?
Growth Is the business getting bigger?
Financial strength Can it pay its bills and debts?
Per share What each share stands for
The share price is 7.22× the book value behind each share.
Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.
All 101 metrics from the data provider
Valuation
Per share
Margins
Growth
Financial strength
Returns & efficiency
Price & volume
Dividends & Corporate Events
Payouts to shareholders, splits and bonus issues, and company meetings — newest first.
- Dividend yield0.00%
- Payout ratio0.00%
No dividends on record.
Corporate calendar
- MeetingAnnual General Meeting
- BoardQuarterly Results
- BoardAudited Results & Others
- BoardQuarterly Results
- MeetingPostal Ballot
- BoardQuarterly Results
- MeetingAnnual General Meeting
- BoardQuarterly Results
Show 7 older events
- BoardAudited Results & Fund Raising
- BoardQuarterly Results
- BoardQuarterly Results
- MeetingAnnual General Meeting
- MeetingAnnual General Meeting
- MeetingAnnual General Meeting
- RightsRights issue of equity shares of ₹ 5/- each in the ratio of 3:10 @ premium of ₹ 220/-.
About Wockhardt
Biotechnology & Drugs
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Key people
- Habil Fakhruddin KhorakiwalaExecutive Chairman of the Board, Founder
- Deepak MadnaniChief Financial Officer
- Rashmi Dinesh MamturaCompliance Officer, Company Secretary
- Murtaza Habil KhorakiwalaManaging Director, Executive Director
- Huzaifa Habil KhorakiwalaExecutive Director
Company facts
- NSE symbolWOCKPHARMA
- BSE code532300
- ISININE049B01025
- IndustryBiotechnology & Drugs
- IndexNIFTY 500
- Market cap₹35,631 Cr
- Revenue (FY26)₹3,373 Cr
- Net profit (FY26)₹213 Cr
In the News
Recent headlines about Wockhardt — they open on Mint in a new tab.
- After the lottery win: why Dr Reddy’s may be doing much more in its laboratories
The pharmaceutical company rode one copycat drug to record profits. Now, co-chairman G.V. Prasad has to prove the company can grow without it. Biosimilars and innovation may hold the answer.
24 Aug 2026 · 11 min read · Mint ↗ - Top Gainers & Losers on 13 August: Apar Industries, Hindalco, Ather Energy, Force Motors, CUB among top losers
Indian stocks slid further, driven down by weak financial participation and high crude oil prices. The Nifty decreased by 0.34% and Sensex by 0.13%, with key sectors like metals and cement seeing significant losses amid ongoing geopolitical tensions.
13 Aug 2026 · 2 min read · Mint ↗ - Top Gainers & Losers on August 12: TCS, Tata Tech, Redington, Godrej Consumer, Wockhardt among top losers
Indian stocks faced downward pressure on August 12 due to rising crude oil prices and weakness in financial and technology sectors. Nifty fell 0.15% to 24,435 and Sensex dropped 0.34% to 77,889, pushing August returns into negative territory.
12 Aug 2026 · 2 min read · Mint ↗ - How three stubborn men, and $1.5 billion poured in over two decades, put India on the world’s new-drug map
While others made money producing generics by copying foreign discoveries, they bet on drug discovery in India, selling the family silver to fund their dreams. Now, after decades, they are seeing a payoff or within kissing distance of one.
27 Jul 2026 · 14 min read · Mint ↗
Stock data comes from the exchange feed via our data provider. It is not real-time and can be delayed, so check the price with your broker before you trade. This page is for information and education only. It is not investment advice, research or a recommendation to buy, sell or hold any security. Investments in the securities market are subject to market risks; read all related documents carefully before investing. See all stocks →